Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orexo
Pharma
Orexo's opioid overdose nasal spray is rejected again by FDA
For the second time in 15 months, the FDA has rejected Orexo’s OX124 (naloxone), a high-dose nasal spray rescue treatment for opioid overdoses.
Kevin Dunleavy
Jul 17, 2024 10:47am
Orexo seeks approval of nasal high-dose opioid rescue medicine
Feb 7, 2023 8:40am
Orexo unveils nasal EpiPen rival, sets sights on 2022 trial
Dec 7, 2021 10:05am
Orexo backs up new digital therapeutic launches with social
Oct 15, 2020 8:10am
